Recognition and repair of the CC-1065-(N3-adenine)-DNA adduct by the UVRABC nucleases

Biochemistry
1988.0

Abstract

The recognition and repair of the helix-stabilizing and relatively nondistortive CC- 1065-(N3 adenine)-DNA adduct by UVRABC nuclease has been investigated both in vivo with 4x174 RFI DNA by a transfection assay and in vitro by a site-directed adduct in a 117 base pair fragment from M13mpl. CC-1065 is a potent antitumor antibiotic produced by Streptomyces zelensis which binds within the minor groove of DNA through N3 of adenine. In contrast to the helix-destabilizing and distortive modifications of DNA caused by ultraviolet light or N-acetoxy-2-(acetylamino)fluorene, CC- 1065 increases the melting point of DNA and decreases the S1 nuclease activity. Using a viral DNA-Escherichia coli transfection system, we have found that the uvrA, uvrB, and uvrC genes, which code for the major excision repair proteins for UV- and NAAAF-induced DNA damage, are also involved in the repair of CC-1065-DNA adducts. In contrast, the uvrD gene product, which has been found to be involved in the repair of UV damage, has no effect in repairing CC-1065-DNA adducts. Purified UVRA, UVRB, and UVRC proteins must work in concert to incise the drug-modified 4x174 RFI DNA. Using a site-directed and multiple CC-1065 modified (MspI-BstNI) 117 base pair fragment from M13mp1, we have found that UVRABC nuclease incises at the eighth phosphodiester bond on the 5'side of the CC-1065-DNA adduct on the drug-modified strand. The enzymes do not cut the noncovalently modified strand. At low drug binding ratios, of the four CC-1065 binding sites identified in the (MspI-BstNI) 117 base pair fragment, GATTA*, GGAAA*, GATAA*, and TTTTA* (* indicates the covalently modified adenine), only the adduct at the high-affinity binding site, GATTA*, is incised by the UVRABC nucleases. No difference in the effect of CC-1065 on local DNA structure, as determined by the DNase I cleavage pattern, was evident among these sites. At high drug binding ratios, a fifth drug binding site, AGCTA*, is identified. At this concentration UVRABC nucleases are unable to incise any of these five CC-1065-DNA adducts. The DNA sequence and/or helix-stabilizing effect of multiple adducts may determine the recognition and/or incision of the drug-DNA adduct by UVRABC nuclease. These results are discussed in relation to the structure of the CC-1065-DNA adduct and the effect of drug binding on local DNA structure.

Knowledge Graph

Similar Paper

Recognition and repair of the CC-1065-(N3-adenine)-DNA adduct by the UVRABC nucleases
Biochemistry 1988.0
Characterization of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex
Nucleic Acids Research 1984.0
Effect of the (+)-CC-1065-(N3-adenine)DNA adduct on in vitro DNA synthesis mediated by Escherichia coli DNA polymerase
Biochemistry 1992.0
Demonstration of the asymmetric effect of CC-1065 on local DNA structure using a site-directed adduct in a 117-base-pair fragment from M13mp1.
Proceedings of the National Academy of Sciences 1987.0
Structure-activity relationships of (+)-CC-1065 analogs in the inhibition of helicase-catalyzed unwinding of duplex DNA
Journal of Medicinal Chemistry 1992.0
Determination of the major tautomeric form of the covalently modified adenine in the (+)-CC-1065-DNA adduct by proton and nitrogen-15 NMR studies
Biochemistry 1990.0
(+)‐CC‐1065 as a probe for intrinsic and protein‐induced bending of DNA
Journal of Molecular Recognition 1994.0
Determination of the structural features of (+)-CC-1065 that are responsible for bending and winding of DNA
Chemical Research in Toxicology 1991.0
Structure of the (+)-CC-1065-DNA adduct: critical role of ordered water molecules and implications for involvement of phosphate catalysis in the covalent reaction
Biochemistry 1991.0
CC-1065 functional analogs possessing different electron-withdrawing substituents and leaving groups: synthesis, kinetics, and sequence specificity of reaction with DNA and biological evaluation
Journal of Medicinal Chemistry 1993.0